{"id":"W2981157362","doi":"10.1016/j.clml.2019.09.022","title":"Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Hazard ratio; Internal medicine; Medicine; Interim analysis; Multiple myeloma; Oncology; Refractory (planetary science); Progression-free survival; Neutropenia; Confidence interval; Randomized controlled trial; Overall survival; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00193378,0.001235187,0.002021543,0.000314091,0.0003562577,0.001526405,0.001063298,0.0009001469,0.002701905],"category_scores_gemma":[0.001012363,0.0002940143,0.002027724,0.000419137,0.0007798029,0.001227941,0.0005651545,0.002935382,0.0006012772],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001647768,"about_ca_system_score_gemma":0.001164814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001256591,"about_ca_topic_score_gemma":0.003692778,"domain_scores_codex":[0.9994743,0.0002592226,0.00001917978,0.00008310449,0.00005070337,0.0001134678],"domain_scores_gemma":[0.9994454,0.0001355232,0.0001212081,0.00005216653,0.00002990805,0.0002158911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8044702,0.01002881,0.005700411,0.001103176,0.004378093,0.000176674,0.0002218702,0.003510601,0.007034841,0.0005507578,0.01034291,0.1524815],"study_design_scores_gemma":[0.8527921,0.1017046,0.02689899,0.0001929369,0.003007633,0.0004188356,0.0001695512,0.001898041,0.001959909,0.001198944,0.009682383,0.00007598442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979943,0.01195052,0.0004032529,0.001489653,0.0002778704,0.0005176723,0.00195626,0.0001470174,0.003314728],"genre_scores_gemma":[0.9833217,0.004508056,0.00123322,0.002775999,0.0003680831,0.0005941285,0.00421856,0.00006491491,0.002915316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002701905,"threshold_uncertainty_score":0.01195544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1096139975023227,"score_gpt":0.3883472726813034,"score_spread":0.2787332751789807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}